PE20140004A1 - Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib - Google Patents

Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib

Info

Publication number
PE20140004A1
PE20140004A1 PE2013001392A PE2013001392A PE20140004A1 PE 20140004 A1 PE20140004 A1 PE 20140004A1 PE 2013001392 A PE2013001392 A PE 2013001392A PE 2013001392 A PE2013001392 A PE 2013001392A PE 20140004 A1 PE20140004 A1 PE 20140004A1
Authority
PE
Peru
Prior art keywords
amino acids
bortezomib
acids seq
compromise
specifically recognize
Prior art date
Application number
PE2013001392A
Other languages
English (en)
Inventor
Jutta Deckert
Michele Mayo
Peter U Park
Pascale Lejeune
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44168449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140004(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20140004A1 publication Critical patent/PE20140004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO HUMANIZADO QUE RECONOCE CD38 SIENDO CAPAZ DE MATAR UNA CELULA CD38+ POR APOPTOSIS, POR CITOTOXICIDAD MEDIADA POR CELULAS DEPENDIENTE DE ANTICUERPOS Y POR CITOTOXICIDAD DEPENDIENTE DEL COMPLEMENTO, EN DONDE DICHO ANTICUERPO COMPRENDE i) UNA CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS SEQ ID N�: 66 QUE COMPRENDE TRES REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD SECUENCIALES QUE TIENEN LAS SECUENCIAS DE AMINOACIDOS SEQ ID N�: 13, 14 Y 15, Y ii) UNA CADENA LIGERA QUE TIENE LA SECUENCIA DE AMINOACIDOS SEQ ID N�: 62 O 64 QUE COMPRENDE TRES REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD SECUENCIALES QUE TIENEN LAS SECUENCIAS DE AMINOACIDOS SEQ ID N�: 16, 17 Y 18; Y B) BORTEZOMIB. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER
PE2013001392A 2010-12-10 2011-12-08 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib PE20140004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306395 2010-12-10

Publications (1)

Publication Number Publication Date
PE20140004A1 true PE20140004A1 (es) 2014-01-23

Family

ID=44168449

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001392A PE20140004A1 (es) 2010-12-10 2011-12-08 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib

Country Status (41)

Country Link
US (1) US9314522B2 (es)
EP (2) EP3412311A1 (es)
JP (1) JP6177133B2 (es)
KR (1) KR101905208B1 (es)
CN (2) CN106334187B (es)
AR (1) AR084196A1 (es)
AU (1) AU2011340472B2 (es)
BR (1) BR112013014370B1 (es)
CA (1) CA2820382C (es)
CL (1) CL2013001670A1 (es)
CO (1) CO6801634A2 (es)
CR (1) CR20130270A (es)
CY (1) CY1121179T1 (es)
DK (1) DK2648747T3 (es)
DO (1) DOP2013000132A (es)
EA (2) EA201692047A1 (es)
EC (1) ECSP13012669A (es)
ES (1) ES2694784T3 (es)
GT (1) GT201300147A (es)
HR (1) HRP20181787T1 (es)
HU (1) HUE039893T2 (es)
IL (1) IL226756B (es)
LT (1) LT2648747T (es)
MA (1) MA34816B1 (es)
MX (1) MX345257B (es)
MY (1) MY165109A (es)
NI (1) NI201300050A (es)
NZ (1) NZ612055A (es)
PE (1) PE20140004A1 (es)
PL (1) PL2648747T3 (es)
PT (1) PT2648747T (es)
RS (1) RS57997B1 (es)
SG (2) SG191059A1 (es)
SI (1) SI2648747T1 (es)
TN (1) TN2013000245A1 (es)
TR (1) TR201816532T4 (es)
TW (1) TWI596116B (es)
UA (1) UA112170C2 (es)
UY (1) UY33791A (es)
WO (1) WO2012076663A1 (es)
ZA (1) ZA201304845B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP6426093B2 (ja) 2012-09-25 2018-11-28 モルフォシス・アーゲー 組み合わせ及びその使用
RU2723937C2 (ru) * 2013-03-13 2020-06-18 Санофи Композиции, включающие антитела к cd38 и карфилзомиб
EP3027648A1 (en) * 2013-08-02 2016-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-claudin 1 antibodies and uses thereof
BR112016009403A2 (pt) * 2013-10-31 2017-09-19 Sanofi Sa Anticorpos anti-cd38 específicos para tratamento de cânceres humanos
SG10201913447SA (en) * 2013-10-31 2020-02-27 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
CR20170587A (es) 2015-06-22 2018-04-03 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
EP3635001A1 (en) 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
CA3072296A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
DE19826517B4 (de) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
JP4912597B2 (ja) 2004-07-13 2012-04-11 パナソニック株式会社 液晶表示装置
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
LT2081595T (lt) * 2006-09-26 2019-07-10 Genmab A/S Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN111909273B (zh) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US8542056B2 (en) * 2010-12-27 2013-09-24 Stmicroelectronics S.Rl. High voltage transmission switch, namely for ultrasound applications
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
RU2723937C2 (ru) 2013-03-13 2020-06-18 Санофи Композиции, включающие антитела к cd38 и карфилзомиб
BR112016009403A2 (pt) 2013-10-31 2017-09-19 Sanofi Sa Anticorpos anti-cd38 específicos para tratamento de cânceres humanos

Also Published As

Publication number Publication date
TN2013000245A1 (en) 2014-11-10
EA201390850A1 (ru) 2013-12-30
AU2011340472B2 (en) 2015-02-12
EA026406B1 (ru) 2017-04-28
TW201307392A (zh) 2013-02-16
CA2820382C (en) 2020-08-18
CN106334187A (zh) 2017-01-18
AU2011340472A1 (en) 2013-05-02
GT201300147A (es) 2017-12-15
US20140186337A1 (en) 2014-07-03
EP2648747B1 (en) 2018-08-08
CA2820382A1 (en) 2012-06-14
IL226756B (en) 2020-06-30
CR20130270A (es) 2013-09-03
BR112013014370B1 (pt) 2020-12-01
SG10201600985XA (en) 2016-03-30
JP2014502280A (ja) 2014-01-30
EP2648747A1 (en) 2013-10-16
RS57997B1 (sr) 2019-01-31
PT2648747T (pt) 2018-11-21
SG191059A1 (en) 2013-08-30
HRP20181787T1 (hr) 2018-12-28
ES2694784T3 (es) 2018-12-27
EA201692047A1 (ru) 2017-06-30
BR112013014370A2 (pt) 2017-05-30
PL2648747T3 (pl) 2019-01-31
CN103282050A (zh) 2013-09-04
TWI596116B (zh) 2017-08-21
AR084196A1 (es) 2013-04-24
CN106334187B (zh) 2021-02-12
ZA201304845B (en) 2014-09-25
JP6177133B2 (ja) 2017-08-09
US9314522B2 (en) 2016-04-19
TR201816532T4 (tr) 2018-11-21
NZ612055A (en) 2014-12-24
CY1121179T1 (el) 2020-05-29
KR20130130774A (ko) 2013-12-02
UY33791A (es) 2012-07-31
CL2013001670A1 (es) 2014-02-28
UA112170C2 (uk) 2016-08-10
MX2013006566A (es) 2013-08-26
ECSP13012669A (es) 2013-08-30
DOP2013000132A (es) 2013-09-30
KR101905208B1 (ko) 2018-10-05
CO6801634A2 (es) 2013-11-29
SI2648747T1 (sl) 2019-04-30
HUE039893T2 (hu) 2019-02-28
LT2648747T (lt) 2018-11-26
MX345257B (es) 2017-01-23
EP3412311A1 (en) 2018-12-12
MA34816B1 (fr) 2014-01-02
CN103282050B (zh) 2016-09-07
MY165109A (en) 2018-02-28
DK2648747T3 (en) 2018-12-03
NI201300050A (es) 2013-08-01
WO2012076663A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20121563A1 (es) Anticuerpos que se unen especificamente al receptor epha2
PE20170665A1 (es) Anticuerpos anti-tau humanizados
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20150002A1 (es) Anticuerpos anti-fcrn
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20110821A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20120562A1 (es) Anticuerpo anti-axl
PE20141045A1 (es) Proteinas de union a bcma (cd269/tnfrsf17)
CL2016001405A1 (es) A peptide mixture

Legal Events

Date Code Title Description
FG Grant, registration